<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>104(8)</volume><submitter>Taha AM</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The management of early breast cancer (BC) includes breast-conserving surgery (BCS), postoperative radiation therapy (PORT) and systemic therapy. Therefore, we aim at evaluating all the efficacy endpoints for PORT compared to no PORT in older women with early-stage BC.&lt;h4>Method&lt;/h4>We searched PubMed, Web of Science, Cochrane, and Scopus databases from inception up to May 2024 for randomized controlled trials (RCTs) where patients were randomized into either PORT vs no PORT. The following outcomes were studied: any local recurrence, nodal recurrence, contralateral BC, distant relapse, all-causes and cancer-specific mortality.&lt;h4>Result&lt;/h4>Seven eligible RCTs with a total of 4860 patients were included; 2435 of them received PORT; and 2425 did not. All patients had a no</pubmed_abstract><journal>Medicine</journal><pagination>e41632</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11857031</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Adjuvant radiotherapy in postmenopausal women with early-stage ER-positive breast cancer: A systematic review and meta-analysis.</pubmed_title><pmcid>PMC11857031</pmcid><pubmed_authors>Taha AM</pubmed_authors><pubmed_authors>Salem DS</pubmed_authors><pubmed_authors>Chapagain S</pubmed_authors><pubmed_authors>Nguyen D</pubmed_authors><pubmed_authors>Saed SAA</pubmed_authors><pubmed_authors>Khlidj Y</pubmed_authors><pubmed_authors>Kamel HA</pubmed_authors><pubmed_authors>Abouelmagd K</pubmed_authors><pubmed_authors>Shash E</pubmed_authors><pubmed_authors>Kassem L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Adjuvant radiotherapy in postmenopausal women with early-stage ER-positive breast cancer: A systematic review and meta-analysis.</name><description>&lt;h4>Background&lt;/h4>The management of early breast cancer (BC) includes breast-conserving surgery (BCS), postoperative radiation therapy (PORT) and systemic therapy. Therefore, we aim at evaluating all the efficacy endpoints for PORT compared to no PORT in older women with early-stage BC.&lt;h4>Method&lt;/h4>We searched PubMed, Web of Science, Cochrane, and Scopus databases from inception up to May 2024 for randomized controlled trials (RCTs) where patients were randomized into either PORT vs no PORT. The following outcomes were studied: any local recurrence, nodal recurrence, contralateral BC, distant relapse, all-causes and cancer-specific mortality.&lt;h4>Result&lt;/h4>Seven eligible RCTs with a total of 4860 patients were included; 2435 of them received PORT; and 2425 did not. All patients had a no</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2025-04-22T20:04:16.448Z</modification><creation>2025-04-06T03:04:45.414Z</creation></dates><accession>S-EPMC11857031</accession><cross_references><pubmed>39993075</pubmed><doi>10.1097/MD.0000000000041632</doi></cross_references></HashMap>